Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Prostate Cancer
 More »

  • Department of Defense Forges New Alliances in War against Prostate...
    for Prostate Disease Research (CPDR) and the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) with the aim of finding new treatments for prostate cancer. ...
    8-9-2013
  • SCT Licenses Worldwide Rights to Prostate Cancer Stem Cell Assets
    Stem Cell Therapeutics (SCT) said today it entered into an option agreement to exclusively license worldwide rights to a series of prostate cancer stem cell assets from the UK's ...
    8-9-2013
  • Making Sense of Small Molecules
    ... planning to roll out diagnostics for cancers, including prostate, bladder, and renal cell carcinoma. Both type 2 diabetes and cancer "are well-known metabolic disease areas," Dr. ...
    8-1-2013
  • Drug Candidates on Trial
    ... The Phase I dose-escalation trial in patients with metastatic castrate resistant prostate cancer was designed to evaluate the safety, tolerability, and clinical outcomes of ...
    7-22-2013
  • ADC, BZL Aim Warheads at PSMA-Positive Prostate Cancers
    potential to pre-empt resistance issues. PSMA is a cell-surface antigen on prostate cancer cells, and PSMA levels correlate directly with an aggressive, metastasizing phenotype. ...
    7-15-2013
  • AstraZeneca Launches Cancer Collaborations
    in testing the potential effectiveness of its investigational therapies olaparib and AZD2014 in high-risk prostate cancer patients who now have a poor disease prognosis. ...
    7-9-2013
  • Even at "Safe" Levels, Potentially Mutagenic Agents in Combination...
    combination of arsenic and estrogen exposure could be harmful, researchers have found. Even at "Safe" Levels, Potentially Mutagenic Agents in Combination Can Cause Prostate Cancer
    7-1-2013
  • Blood-Based Tumor Sequence
    New therapies that can specifically target cancer-driving mutations have improved treatment outcomes in breast, lung, and prostate cancer. The result has been a much more targeted ...
    7-1-2013
  • Reducing the Cost of Peptide Synthesis
    Examples of peptide-based cancer therapeutics include luteinizing hormone-releasing hormone (LHRH) agonists to decrease testosterone production in prostate cancer, somatostatin ...
    7-1-2013
  • J&J Acquiring Aragon for Up To $1B
    Johnson & Johnson said today it will acquire Aragon Pharmaceuticals for up to $1 billion, in a deal that will grow the pharma giant's prostate cancer portfolio by adding a drug ...
    6-17-2013
  • More Than a Messenger: A New Class of Drugs-mRNA-Based Therapeutics
    ... vaccines lack. 5 Early clinical studies in patients with castration-resistant prostate cancer and lung cancer have shown the favorable safety profile of this approach. ...
    6-14-2013
  • Isis Wins $10M After AstraZeneca Adds Prostate Cancer Drug to...
    in December 2012. The candidate, ISIS-AR Rx , is an antisense drug designed to treat patients with prostate cancer by inhibiting the production of the androgen receptor (AR). ...
    6-3-2013
  • Vaccine Advances Drive Differentiation
    Mosquirix(tm) (malaria), Vaccinogen's OncoVax® (cancer), Dendreon's Provenge® (prostate cancer), and Diamyd Medical's Diamyd® (diabetes) during the next five years is likely to ...
    6-1-2013
  • Empire Genomics Nabs Prostate Cancer Biomarker from Cornell
    for its use in developing a molecular diagnostic test that could help physicians diagnose and determine treatment options for patients with neuroendocrine prostate cancer (NEPC). ...
    5-22-2013
  • Cancer's Bitter Medicine
    ... Dendreon raised eyebrows in 2010 when it launched prostate cancer drug Provenge with a $93,000 price tag that investors blamed for the company missing initial sales forecasts. ...
    5-21-2013
  • More »

    Journal Articles

  • Cutaneous Metastases of Prostate Cancer
    Catherine Bailey, Andrew Broadbent
    Journal of Palliative Medicine
    Cutaneous Metastases of Prostate Cancer Journal of Palliative Medicine
  • miR-205 hinders the malignant interplay between prostate cancer...
    Paolo Gandellini, Elisa Giannoni, Anna Casamichele, Maria Letizia Taddei, Maurizio Callari, Claudia Piovan, Riccardo Valdagni, Marco Alessandro Pierotti, Nadia Zaffaroni, Paola Chiarugi
    Antioxidants & Redox Signaling
    miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts Antioxidants & Redox Signaling
  • Learning curve and perioperative outcomes of robot assisted radical...
    Takeshi Hashimoto, Kunihiko Yoshioka, Tatsuo Gondo, Naohiro kamoda, Choichiro Ozu, Yutaka Horiguchi, Kazunori Namiki, Jun Nakashima, Masaaki Tachibana
    Journal of Endourologyand Part B, Videourology
    Objectives: The aim of the present study was to investigate the learning curve and perioperative outcomes in 200 consecutive patients with prostate cancer who underwent ...
  • Factors Influencing Health Related Quality of Life in Cancer...
    Erin Wong, Edward Chow, Liying Zhang, Gillian Bedard, Kinsey Lam, Alysa Fairchild, Vassilios Vassiliou, Mohamed A. Alm El-Din, Reynaldo Jesus-Garcia, Aswin Kumar, Fabien Forges, Ling-Ming Tseng, Ming-Feng Hou, Wei-Chu Chie, Andrew Bottomley
    Journal of Palliative Medicine
    KPS > 80 and prostate primary histology were predictive of better HRQOL in the PA scale. KPS > 80 and primary cancer site were confirmed as significant predictive factors in ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Top Paid Women in Biopharma

Do you think the women on our list of the 20 top paid women executives in biopharma are underpaid?

Suggest a Poll